Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.50.

FOLD has been the subject of several recent research reports. Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Bank of America increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Finally, Guggenheim increased their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday.

Check Out Our Latest Stock Analysis on Amicus Therapeutics

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,401 shares of company stock valued at $352,038. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its position in Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after buying an additional 2,307,385 shares during the period. William Blair Investment Management LLC raised its holdings in Amicus Therapeutics by 12.8% during the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after purchasing an additional 1,477,084 shares during the last quarter. Fiera Capital Corp raised its holdings in Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Amicus Therapeutics by 14.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock worth $29,964,000 after purchasing an additional 378,999 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Amicus Therapeutics by 17.9% during the 2nd quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company’s stock worth $22,558,000 after purchasing an additional 345,117 shares during the last quarter.

Amicus Therapeutics Stock Down 2.3 %

Amicus Therapeutics stock opened at $10.98 on Friday. The stock has a market capitalization of $3.26 billion, a PE ratio of -28.15 and a beta of 0.68. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The company has a 50 day moving average of $11.14 and a 200-day moving average of $10.61.

Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. During the same quarter in the prior year, the company earned ($0.15) earnings per share. The business’s quarterly revenue was up 34.0% compared to the same quarter last year. On average, equities research analysts anticipate that Amicus Therapeutics will post -0.06 EPS for the current fiscal year.

About Amicus Therapeutics

(Get Free Report

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Read More